随机临床试验:高剂量口服硫胺素对比安慰剂治疗静息期炎症性肠病患者慢性疲劳
这项随机双盲安慰剂对照交叉试验纳入40例静息期炎症性肠病伴严重慢性疲劳患者,评估基于性别和体重的高剂量口服硫胺素(600-1800 mg/d)的疗效与安全性。交叉分析显示硫胺素组疲劳评分平均降低4.5分(95%CI 2.6-6.2),安慰剂组平均升高0.75分(95%CI -1.3-2.8;P=0.0003)。仅见轻度副作用,治疗耐受良好。
要点
- 高剂量口服硫胺素(600-1800 mg/d)使静息期炎症性肠病患者疲劳评分平均降低4.5分,安慰剂组平均升高0.75分。
- 第1组55%、第2组75%的患者在硫胺素治疗期间疲劳改善≥3分,安慰剂期间分别为25%和35%。
- 仅观察到轻度副作用,高剂量口服硫胺素耐受良好。
核心结论
- 高剂量口服硫胺素对炎症性肠病患者的慢性疲劳有显著获益,且治疗耐受良好。
研究设计与样本
- 随机、双盲、安慰剂对照交叉试验,纳入40例静息期炎症性肠病伴严重慢性疲劳且无其他疲劳原因的患者,2018年11月至2019年10月入组。
- 患者按1:1分配至序贯1(高剂量口服硫胺素4周、洗脱4周、口服安慰剂4周)或序贯2(口服安慰剂4周、洗脱4周、高剂量口服硫胺素4周)。
- 硫胺素剂量为600-1800 mg/d,根据性别和体重确定。
- 疲劳采用炎症性肠病疲劳问卷测量,主要结局为硫胺素治疗4周后疲劳改善≥3分。
主要发现
- 交叉分析显示硫胺素治疗后疲劳评分平均降低4.5分(95%CI 2.6-6.2),安慰剂后平均升高0.75分(95%CI -1.3-2.8;P=0.0003)。
- 第1组55%、第2组75%的患者在硫胺素治疗期间疲劳改善≥3分,而安慰剂期间第1组25%、第2组35%。
- 仅检测到轻度副作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fatigue is a burdensome symptom for patients with inflammatory bowel disease (IBD). Few pharmacological interventions have documented effect on fatigue in patients with IBD. A pilot study indicated a 20-day effect with high-dose thiamine. AIMS: To investigate the effect and safety of high-dose oral thiamine (600-1800 mg/d) based on gender and weight on chronic fatigue in patients with quiescent IBD. METHODS: This was a randomised, double-blinded, placebo-controlled crossover trial. Patients had quiescent IBD, severe chronic fatigue and no other explanation for fatigue. Patients were allocated 1:1 to either 1) high-dose oral thiamine for 4 weeks, 4 weeks of washout, 4 weeks of oral placebo or 2) oral placebo for 4 weeks, 4 weeks of washout, 4 weeks of high-dose oral thiamine. Fatigue was measured using the Inflammatory Bowel Disease-Fatigue Questionnaire. The primary outcome was improvement (≥3 points) of fatigue after 4 weeks on thiamine. RESULTS: Forty patients were enrolled between November 2018 and October 2019. Crossover analysis showed a mean reduction of 4.5 points (95% CI 2.6-6.2) in fatigue after thiamine compared with a mean increase of 0.75 point (95% CI -1.3-2.8; P = 0.0003) after placebo. Furthermore, 55% of group 1 and 75% of group 2 showed an improvement ≥ 3 points while on thiamine compared with 25% of group 1 and 35% of group 2 while on placebo. Only mild side effects were detected. CONCLUSION: We showed a significant beneficial effect of high-dose oral thiamine on chronic fatigue in IBD. The treatment was well tolerated. TRIAL REGISTRATION: NCT03634735.
引用
- Bager P, Hvas CL, Rud CL, et al. Randomised clinical trial: high-dose oral thiamine versus placebo for chronic fatigue in patients with quiescent inflammatory bowel disease. Aliment Pharmacol Ther. 2020. PMID: 33210299. doi:10.1111/apt.16166
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。